Navigation Links
Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
Date:10/21/2009

tatements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2009, filed with the SEC on August 6, 2009, as well as other filings by the company with the SEC.

SOURCE Micromet, Inc.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
2. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
3. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
6. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
7. Micromet Key Events for 2009
8. Micromet Expands Committed Equity Financing Facility to $75 Million
9. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
11. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... XTENT, Inc.,(Nasdaq: XTNT ) today announced a ... Notified Body for CE Mark approval of its ... that recently,presented six-month follow up results from the ... Agency, which reviews the drug formulation,submission of XTENT,s ...
... Make Qnexa the New Clinical Gold, Standard Drug ... Resources, WALTHAM, Mass., June 12 Decision Resources, ... on pharmaceutical and,healthcare issues, finds that a drug that ... would earn a 40 percent patient share in,the obesity ...
Cached Medicine Technology:XTENT Announces European Regulatory Update 2XTENT Announces European Regulatory Update 3A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market 2
(Date:7/25/2014)... July 25, 2014 DON’T PAUSE is a ... uncomfortable bloating, hot flashes, mood swings, burning tongue menopause ... Dr. Shoreh Ershadi. The AntiAging Institute of California is now ... allows women to try this revolutionary product. For a limited ... get a third bottle at no charge. , ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Dietary changes can dramatically ... a daily basis, according to a new study. ... might help detect and ease flare-ups for people with ... colitis and Crohn,s disease), the researchers said. Trillions ... effect on human health isn,t well understood, the Massachusetts ...
(Date:7/25/2014)... San Francisco, Ca (PRWEB) July 25, 2014 ... in business with their Anniversary Futon Sale. The Futon Shop ... mom and pop shop, which has grown from a few ... States over 33 different kinds of futon mattresses. , ... mouth in the beginning and the desire to sleep on ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 In an election ... it’s no surprise that Americans may not be sleeping well, ... according to a new poll conducted by US-Mattress . ... from across the country, “Which Political Party Do You Side ... that those registered as Independents tout a higher rate of ...
(Date:7/25/2014)... the U.S. are living with a brain tumor, and ... factors, scientists are still searching for answers. , "Right ... and we don,t know why people develop brain tumors," ... Brain Tumor Association. "It,s frustrating for the brain tumor ... funds research to pursue answers to these questions, and ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 2Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 3Health News:Brain tumor causes and risk factors elude scientists 2
... Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: ... today its consolidated,results for the fourth quarter 2007 ... financial information is presented on a consolidated basis,and ... Law and the,Accounts Chart of the Agencia Nacional ...
... 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Brothers Global Healthcare Conference on Wednesday, March 19,at ... a live webcast of,the presentation at:, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=OnyxPharmaceu ,tic ... on 15 minutes early in order to,register and ...
... new study in the,Journal of the American Medical ... (methicillin-resistant Staphylococus aureus), a simple,skin or nasal swab, ... Screening for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and ... 10, March 12, 2008)., The findings of ...
... 11 Eli Manning, NFL Most,Valuable Player 2008 ... New,York Giants, will address a National Press Club ... national challenge to encourage Americans to be,more active., ... the President,s Council on,Physical Fitness and Sports, Manning ...
... Inc.,(NYSE: RBN ) announced today that it will ... the period ended February 29, 2008, after,market close on ... conference,call will be held at 2:00 p.m., EDT on ... Chief Executive Officer, and Christopher M. Hix,Vice President and ...
... Center have teased out two distinct sets of risk ... are two completely different kinds of the disease. , ... caused by the human papillomavirus (HPV), a common sexually ... behaviors and marijuana use, rather than tobacco and alcohol. ...
Cached Medicine News:Health News:Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007 2Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:Researchers ID behavioral risk factors for head and neck cancers 2Health News:Researchers ID behavioral risk factors for head and neck cancers 3
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... is the newest real-time PCR instrument offered ... offers six detection channels that provide fluorescence ... and 710nm. Perform rapid PCR due to ... with glass capillaries. Virtually any published protocol ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
... standard in QPCR with the Mx4000 multiplex ... superior performance, more flexibility, and reasonable pricing. ... with Windows 98SE and Pentium III (or ... Speakers, Surge Protector (US only), Mx4000 Software ...
Medicine Products: